Adjuvant Radiotherapy for Palpable Melanoma Metastases to the Groin: When to Irradiate?
Purpose To determine the efficacy of and criteria for postoperative radiotherapy (PORT) in patients with palpable melanoma metastases to the groin. Methods and Materials Patients with palpable metastases to the groin who were treated with therapeutic nodal dissection during 2000 to 2006 were identif...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2012-05, Vol.83 (1), p.310-316 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 316 |
|---|---|
| container_issue | 1 |
| container_start_page | 310 |
| container_title | International journal of radiation oncology, biology, physics |
| container_volume | 83 |
| creator | Gojkovič-Horvat, Andreja, M.D Jančar, Boris, M.D., M.Sc Blas, Mateja, Ph.D Žumer, Barbara, M.D Karner, Katarina, M.D., M.Sc Hočevar, Marko, M.D., Ph.D Strojan, Primož, M.D., Ph.D |
| description | Purpose To determine the efficacy of and criteria for postoperative radiotherapy (PORT) in patients with palpable melanoma metastases to the groin. Methods and Materials Patients with palpable metastases to the groin who were treated with therapeutic nodal dissection during 2000 to 2006 were identified in a prospective institutional database. Results In 101 patients, 103 therapeutic nodal dissections were performed; 37 of these were treated with PORT to a median equivalent dose (eqTD2 ) of 50.6 Gy (range, 50–72 Gy). In the surgery-only and PORT groups, 2-year regional control rates were 86% (95% confidence interval [CI] 76–95%) and 91% (95% CI, 81–100%), respectively ( p = 0.395). Of five recurrences in radiation-treated patients, four were of dermal type, and in three of these cases, no bolus over the operative scar was used. PORT improved 2-year regional control (46% [95% CI, 11–82%] vs. 82% [95% CI, 63–100%], p = 0.022) among patients in which the sum of risk factors present ( i.e. , risk factor score) was ≥2. In multivariate analysis, risk-factor score ( |
| doi_str_mv | 10.1016/j.ijrobp.2011.06.1979 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22056348</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0360301611028677</els_id><sourcerecordid>1008840779</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-97514224a60f4a0261d9970de7f822637f82d25a605ee8e76cb86344f86696593</originalsourceid><addsrcrecordid>eNqNkl2L1TAQhoMo7nH1JygFEbxpTdLmo17ssiy6LqwofrDehZx0ykntSWqSLpx_b0qPCt4oBCZMnpnJzDsIPSW4IpjwV0Nlh-C3U0UxIRXmFWlFew9tiBRtWTP27T7a4Jrjss70CXoU44BxRkXzEJ1QimvGOd2g24tumO-0S8Un3VmfdhD0dCh6H4qPepz0doTiPYza-b3Ol6RjPhCL5IvMFlfBW_e6uN2BW1zXIeQsOsH5Y_Sg12OEJ0d7ir6-ffPl8l158-Hq-vLipjSMkFS2gpGG0kZz3DcaU066thW4A9FLSnm9mI6y_MwAJAhutpLXTdNLzlvO2voUPV_z-pisisYmMDvjnQOTVG6TZVpm6uVKTcH_mCEmtbfRwJj7Aj9HRbgUnBOC_wPFWMoGC7HUZitqgo8xQK-mYPc6HDKkFpHUoFaR1CKSwlwtIuW4Z8cS83YP3e-oX6pk4MUR0NHosQ_aGRv_cExSIVuSufOVgzzhOwthGQA4A50NS_-dt__8ytlfGcxonc1Fv8MB4uDn4LJ8iqhIFVafl41aFiqPikouRP0TGxHDqQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1008840779</pqid></control><display><type>article</type><title>Adjuvant Radiotherapy for Palpable Melanoma Metastases to the Groin: When to Irradiate?</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Gojkovič-Horvat, Andreja, M.D ; Jančar, Boris, M.D., M.Sc ; Blas, Mateja, Ph.D ; Žumer, Barbara, M.D ; Karner, Katarina, M.D., M.Sc ; Hočevar, Marko, M.D., Ph.D ; Strojan, Primož, M.D., Ph.D</creator><creatorcontrib>Gojkovič-Horvat, Andreja, M.D ; Jančar, Boris, M.D., M.Sc ; Blas, Mateja, Ph.D ; Žumer, Barbara, M.D ; Karner, Katarina, M.D., M.Sc ; Hočevar, Marko, M.D., Ph.D ; Strojan, Primož, M.D., Ph.D</creatorcontrib><description>Purpose To determine the efficacy of and criteria for postoperative radiotherapy (PORT) in patients with palpable melanoma metastases to the groin. Methods and Materials Patients with palpable metastases to the groin who were treated with therapeutic nodal dissection during 2000 to 2006 were identified in a prospective institutional database. Results In 101 patients, 103 therapeutic nodal dissections were performed; 37 of these were treated with PORT to a median equivalent dose (eqTD2 ) of 50.6 Gy (range, 50–72 Gy). In the surgery-only and PORT groups, 2-year regional control rates were 86% (95% confidence interval [CI] 76–95%) and 91% (95% CI, 81–100%), respectively ( p = 0.395). Of five recurrences in radiation-treated patients, four were of dermal type, and in three of these cases, no bolus over the operative scar was used. PORT improved 2-year regional control (46% [95% CI, 11–82%] vs. 82% [95% CI, 63–100%], p = 0.022) among patients in which the sum of risk factors present ( i.e. , risk factor score) was ≥2. In multivariate analysis, risk-factor score (<2 vs. ≥2: HR, 2.93; 95% CI, 1.00–8.56; p < 0.0001) and PORT (yes vs. no: HR, 7.81; 95% CI, 2.83–21.74; p = 0.050) was predictive for regional control and on logistic-regression testing, number of involved lymph nodes was predictive for systemic dissemination ( p = 0.011). Conclusions PORT should follow therapeutic nodal dissection in cases with two or more adverse factors. More conventional fractionation (≤2.5 Gy), cumulative eqTD2 <60 Gy and use of bolus over the operative scar are recommended.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2011.06.1979</identifier><identifier>PMID: 22035662</identifier><identifier>CODEN: IOBPD3</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Cause of Death ; Cicatrix ; Confidence Intervals ; Dermatology ; Female ; FRACTIONATION ; Groin ; GY RANGE 10-100 ; HAZARDS ; Hematology, Oncology and Palliative Medicine ; Humans ; IRRADIATION ; Leg ; Lymph Node Excision - adverse effects ; Lymph Node Excision - methods ; Lymph Node Excision - utilization ; LYMPH NODES ; Lymphatic Irradiation ; Lymphatic Metastasis ; Lymphedema - etiology ; Male ; Medical sciences ; Melanoma ; Melanoma - mortality ; Melanoma - pathology ; Melanoma - radiotherapy ; Melanoma - secondary ; Melanoma - surgery ; MELANOMAS ; METASTASES ; Middle Aged ; MULTIVARIATE ANALYSIS ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - radiotherapy ; Palpation ; PATIENTS ; Prospective Studies ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOTHERAPY ; Radiotherapy Dosage ; Radiotherapy, Adjuvant - adverse effects ; Radiotherapy, Adjuvant - methods ; Regional control ; Retrospective Studies ; Risk Factors ; Skin Neoplasms ; SURGERY ; Tumors of the skin and soft tissue. Premalignant lesions ; Young Adult</subject><ispartof>International journal of radiation oncology, biology, physics, 2012-05, Vol.83 (1), p.310-316</ispartof><rights>Elsevier Inc.</rights><rights>2012 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-97514224a60f4a0261d9970de7f822637f82d25a605ee8e76cb86344f86696593</citedby><cites>FETCH-LOGICAL-c511t-97514224a60f4a0261d9970de7f822637f82d25a605ee8e76cb86344f86696593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2011.06.1979$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,315,782,786,887,3552,27931,27932,46002</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25827891$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22035662$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22056348$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Gojkovič-Horvat, Andreja, M.D</creatorcontrib><creatorcontrib>Jančar, Boris, M.D., M.Sc</creatorcontrib><creatorcontrib>Blas, Mateja, Ph.D</creatorcontrib><creatorcontrib>Žumer, Barbara, M.D</creatorcontrib><creatorcontrib>Karner, Katarina, M.D., M.Sc</creatorcontrib><creatorcontrib>Hočevar, Marko, M.D., Ph.D</creatorcontrib><creatorcontrib>Strojan, Primož, M.D., Ph.D</creatorcontrib><title>Adjuvant Radiotherapy for Palpable Melanoma Metastases to the Groin: When to Irradiate?</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose To determine the efficacy of and criteria for postoperative radiotherapy (PORT) in patients with palpable melanoma metastases to the groin. Methods and Materials Patients with palpable metastases to the groin who were treated with therapeutic nodal dissection during 2000 to 2006 were identified in a prospective institutional database. Results In 101 patients, 103 therapeutic nodal dissections were performed; 37 of these were treated with PORT to a median equivalent dose (eqTD2 ) of 50.6 Gy (range, 50–72 Gy). In the surgery-only and PORT groups, 2-year regional control rates were 86% (95% confidence interval [CI] 76–95%) and 91% (95% CI, 81–100%), respectively ( p = 0.395). Of five recurrences in radiation-treated patients, four were of dermal type, and in three of these cases, no bolus over the operative scar was used. PORT improved 2-year regional control (46% [95% CI, 11–82%] vs. 82% [95% CI, 63–100%], p = 0.022) among patients in which the sum of risk factors present ( i.e. , risk factor score) was ≥2. In multivariate analysis, risk-factor score (<2 vs. ≥2: HR, 2.93; 95% CI, 1.00–8.56; p < 0.0001) and PORT (yes vs. no: HR, 7.81; 95% CI, 2.83–21.74; p = 0.050) was predictive for regional control and on logistic-regression testing, number of involved lymph nodes was predictive for systemic dissemination ( p = 0.011). Conclusions PORT should follow therapeutic nodal dissection in cases with two or more adverse factors. More conventional fractionation (≤2.5 Gy), cumulative eqTD2 <60 Gy and use of bolus over the operative scar are recommended.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Cause of Death</subject><subject>Cicatrix</subject><subject>Confidence Intervals</subject><subject>Dermatology</subject><subject>Female</subject><subject>FRACTIONATION</subject><subject>Groin</subject><subject>GY RANGE 10-100</subject><subject>HAZARDS</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>IRRADIATION</subject><subject>Leg</subject><subject>Lymph Node Excision - adverse effects</subject><subject>Lymph Node Excision - methods</subject><subject>Lymph Node Excision - utilization</subject><subject>LYMPH NODES</subject><subject>Lymphatic Irradiation</subject><subject>Lymphatic Metastasis</subject><subject>Lymphedema - etiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Melanoma</subject><subject>Melanoma - mortality</subject><subject>Melanoma - pathology</subject><subject>Melanoma - radiotherapy</subject><subject>Melanoma - secondary</subject><subject>Melanoma - surgery</subject><subject>MELANOMAS</subject><subject>METASTASES</subject><subject>Middle Aged</subject><subject>MULTIVARIATE ANALYSIS</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - radiotherapy</subject><subject>Palpation</subject><subject>PATIENTS</subject><subject>Prospective Studies</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>RADIOTHERAPY</subject><subject>Radiotherapy Dosage</subject><subject>Radiotherapy, Adjuvant - adverse effects</subject><subject>Radiotherapy, Adjuvant - methods</subject><subject>Regional control</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Skin Neoplasms</subject><subject>SURGERY</subject><subject>Tumors of the skin and soft tissue. Premalignant lesions</subject><subject>Young Adult</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkl2L1TAQhoMo7nH1JygFEbxpTdLmo17ssiy6LqwofrDehZx0ykntSWqSLpx_b0qPCt4oBCZMnpnJzDsIPSW4IpjwV0Nlh-C3U0UxIRXmFWlFew9tiBRtWTP27T7a4Jrjss70CXoU44BxRkXzEJ1QimvGOd2g24tumO-0S8Un3VmfdhD0dCh6H4qPepz0doTiPYza-b3Ol6RjPhCL5IvMFlfBW_e6uN2BW1zXIeQsOsH5Y_Sg12OEJ0d7ir6-ffPl8l158-Hq-vLipjSMkFS2gpGG0kZz3DcaU066thW4A9FLSnm9mI6y_MwAJAhutpLXTdNLzlvO2voUPV_z-pisisYmMDvjnQOTVG6TZVpm6uVKTcH_mCEmtbfRwJj7Aj9HRbgUnBOC_wPFWMoGC7HUZitqgo8xQK-mYPc6HDKkFpHUoFaR1CKSwlwtIuW4Z8cS83YP3e-oX6pk4MUR0NHosQ_aGRv_cExSIVuSufOVgzzhOwthGQA4A50NS_-dt__8ytlfGcxonc1Fv8MB4uDn4LJ8iqhIFVafl41aFiqPikouRP0TGxHDqQ</recordid><startdate>20120501</startdate><enddate>20120501</enddate><creator>Gojkovič-Horvat, Andreja, M.D</creator><creator>Jančar, Boris, M.D., M.Sc</creator><creator>Blas, Mateja, Ph.D</creator><creator>Žumer, Barbara, M.D</creator><creator>Karner, Katarina, M.D., M.Sc</creator><creator>Hočevar, Marko, M.D., Ph.D</creator><creator>Strojan, Primož, M.D., Ph.D</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope><scope>OTOTI</scope></search><sort><creationdate>20120501</creationdate><title>Adjuvant Radiotherapy for Palpable Melanoma Metastases to the Groin: When to Irradiate?</title><author>Gojkovič-Horvat, Andreja, M.D ; Jančar, Boris, M.D., M.Sc ; Blas, Mateja, Ph.D ; Žumer, Barbara, M.D ; Karner, Katarina, M.D., M.Sc ; Hočevar, Marko, M.D., Ph.D ; Strojan, Primož, M.D., Ph.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-97514224a60f4a0261d9970de7f822637f82d25a605ee8e76cb86344f86696593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Cause of Death</topic><topic>Cicatrix</topic><topic>Confidence Intervals</topic><topic>Dermatology</topic><topic>Female</topic><topic>FRACTIONATION</topic><topic>Groin</topic><topic>GY RANGE 10-100</topic><topic>HAZARDS</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>IRRADIATION</topic><topic>Leg</topic><topic>Lymph Node Excision - adverse effects</topic><topic>Lymph Node Excision - methods</topic><topic>Lymph Node Excision - utilization</topic><topic>LYMPH NODES</topic><topic>Lymphatic Irradiation</topic><topic>Lymphatic Metastasis</topic><topic>Lymphedema - etiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Melanoma</topic><topic>Melanoma - mortality</topic><topic>Melanoma - pathology</topic><topic>Melanoma - radiotherapy</topic><topic>Melanoma - secondary</topic><topic>Melanoma - surgery</topic><topic>MELANOMAS</topic><topic>METASTASES</topic><topic>Middle Aged</topic><topic>MULTIVARIATE ANALYSIS</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - radiotherapy</topic><topic>Palpation</topic><topic>PATIENTS</topic><topic>Prospective Studies</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>RADIOTHERAPY</topic><topic>Radiotherapy Dosage</topic><topic>Radiotherapy, Adjuvant - adverse effects</topic><topic>Radiotherapy, Adjuvant - methods</topic><topic>Regional control</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Skin Neoplasms</topic><topic>SURGERY</topic><topic>Tumors of the skin and soft tissue. Premalignant lesions</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gojkovič-Horvat, Andreja, M.D</creatorcontrib><creatorcontrib>Jančar, Boris, M.D., M.Sc</creatorcontrib><creatorcontrib>Blas, Mateja, Ph.D</creatorcontrib><creatorcontrib>Žumer, Barbara, M.D</creatorcontrib><creatorcontrib>Karner, Katarina, M.D., M.Sc</creatorcontrib><creatorcontrib>Hočevar, Marko, M.D., Ph.D</creatorcontrib><creatorcontrib>Strojan, Primož, M.D., Ph.D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>OSTI.GOV</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gojkovič-Horvat, Andreja, M.D</au><au>Jančar, Boris, M.D., M.Sc</au><au>Blas, Mateja, Ph.D</au><au>Žumer, Barbara, M.D</au><au>Karner, Katarina, M.D., M.Sc</au><au>Hočevar, Marko, M.D., Ph.D</au><au>Strojan, Primož, M.D., Ph.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjuvant Radiotherapy for Palpable Melanoma Metastases to the Groin: When to Irradiate?</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2012-05-01</date><risdate>2012</risdate><volume>83</volume><issue>1</issue><spage>310</spage><epage>316</epage><pages>310-316</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><coden>IOBPD3</coden><abstract>Purpose To determine the efficacy of and criteria for postoperative radiotherapy (PORT) in patients with palpable melanoma metastases to the groin. Methods and Materials Patients with palpable metastases to the groin who were treated with therapeutic nodal dissection during 2000 to 2006 were identified in a prospective institutional database. Results In 101 patients, 103 therapeutic nodal dissections were performed; 37 of these were treated with PORT to a median equivalent dose (eqTD2 ) of 50.6 Gy (range, 50–72 Gy). In the surgery-only and PORT groups, 2-year regional control rates were 86% (95% confidence interval [CI] 76–95%) and 91% (95% CI, 81–100%), respectively ( p = 0.395). Of five recurrences in radiation-treated patients, four were of dermal type, and in three of these cases, no bolus over the operative scar was used. PORT improved 2-year regional control (46% [95% CI, 11–82%] vs. 82% [95% CI, 63–100%], p = 0.022) among patients in which the sum of risk factors present ( i.e. , risk factor score) was ≥2. In multivariate analysis, risk-factor score (<2 vs. ≥2: HR, 2.93; 95% CI, 1.00–8.56; p < 0.0001) and PORT (yes vs. no: HR, 7.81; 95% CI, 2.83–21.74; p = 0.050) was predictive for regional control and on logistic-regression testing, number of involved lymph nodes was predictive for systemic dissemination ( p = 0.011). Conclusions PORT should follow therapeutic nodal dissection in cases with two or more adverse factors. More conventional fractionation (≤2.5 Gy), cumulative eqTD2 <60 Gy and use of bolus over the operative scar are recommended.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>22035662</pmid><doi>10.1016/j.ijrobp.2011.06.1979</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-3016 |
| ispartof | International journal of radiation oncology, biology, physics, 2012-05, Vol.83 (1), p.310-316 |
| issn | 0360-3016 1879-355X |
| language | eng |
| recordid | cdi_osti_scitechconnect_22056348 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adolescent Adult Aged Aged, 80 and over Biological and medical sciences Cause of Death Cicatrix Confidence Intervals Dermatology Female FRACTIONATION Groin GY RANGE 10-100 HAZARDS Hematology, Oncology and Palliative Medicine Humans IRRADIATION Leg Lymph Node Excision - adverse effects Lymph Node Excision - methods Lymph Node Excision - utilization LYMPH NODES Lymphatic Irradiation Lymphatic Metastasis Lymphedema - etiology Male Medical sciences Melanoma Melanoma - mortality Melanoma - pathology Melanoma - radiotherapy Melanoma - secondary Melanoma - surgery MELANOMAS METASTASES Middle Aged MULTIVARIATE ANALYSIS Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - radiotherapy Palpation PATIENTS Prospective Studies Radiology RADIOLOGY AND NUCLEAR MEDICINE RADIOTHERAPY Radiotherapy Dosage Radiotherapy, Adjuvant - adverse effects Radiotherapy, Adjuvant - methods Regional control Retrospective Studies Risk Factors Skin Neoplasms SURGERY Tumors of the skin and soft tissue. Premalignant lesions Young Adult |
| title | Adjuvant Radiotherapy for Palpable Melanoma Metastases to the Groin: When to Irradiate? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T01%3A08%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjuvant%20Radiotherapy%20for%20Palpable%20Melanoma%20Metastases%20to%20the%20Groin:%20When%20to%20Irradiate?&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Gojkovi%C4%8D-Horvat,%20Andreja,%20M.D&rft.date=2012-05-01&rft.volume=83&rft.issue=1&rft.spage=310&rft.epage=316&rft.pages=310-316&rft.issn=0360-3016&rft.eissn=1879-355X&rft.coden=IOBPD3&rft_id=info:doi/10.1016/j.ijrobp.2011.06.1979&rft_dat=%3Cproquest_osti_%3E1008840779%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1008840779&rft_id=info:pmid/22035662&rft_els_id=1_s2_0_S0360301611028677&rfr_iscdi=true |